Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-hodgkin lymphoma

Journal of Nuclear Medicine

Volumn 54, Issue 9, 2013, Pages 1535-1542

  Hobbs, Robert F ^a   Wahl, Richard L ^a   Frey, Eric C ^a   Kasamon, Yvette ^a   Song, Hong ^a   Huang, Peng ^a   Jones, Richard J ^a   Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BED; Dosimetry; Lymphoma; Radiopharmaceutical therapy; Treatment planning

Indexed keywords

IBRITUMOMAB TIUXETAN; MYELOABLATIVE AGENT; RADIOPHARMACEUTICAL AGENT; TOSITUMOMAB I 131; ANTINEOPLASTIC AGENT; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY; YTTRIUM;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; HUMAN; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROCESS OPTIMIZATION; THREE DIMENSIONAL IMAGING; TREATMENT INDICATION; BED; BIOLOGICAL MODEL; COMPUTER ASSISTED DRUG THERAPY; COMPUTER SIMULATION; LYMPHOMA; METHODOLOGY; RADIATION DOSE; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICAL THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING;

BED; DOSIMETRY; LYMPHOMA; RADIOPHARMACEUTICAL THERAPY; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG THERAPY, COMPUTER-ASSISTED; HUMANS; MODELS, BIOLOGICAL; MYELOABLATIVE AGONISTS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84887325683     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.117952     Document Type: Article

References (35)

1. Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplant. 2005;36:1021-1026.
2. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902-1909.
3. Walrand S, Hanin FX, Pauwels S, Jamar F. Tumour control probability derived from dose distribution in homogeneous and heterogeneous models: assuming similar pharmacokinetics, 125Sn-177Lu is superior to 90Y-177Lu in peptide receptor radiotherapy. Phys Med Biol. 2012;57:4263-4275.
4. Villard L, Romer A, Marincek N, et al. Cohort study of somatostatin-based radiopeptide therapy with [90Y-DOTA]-TOC versus [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012;30:1100-1106.
5. Kunikowska J, Krolicki L, Hubalewska-Dydejczyk A, Mikolajczak R, Sowa- Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38:1788-1797.
6. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):13S-17S.
7. Frilling A, Weber F, Saner F, et al. Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006;140:968-976.
8. Seregni E, Maccauro M, Coliva A, et al. Treatment with tandem [90Y]DOTATATE and [177Lu]DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging. 2010;54:84-91.
9. Madsen MT, Bushnell DL, Juweid ME, et al. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. J Nucl Med. 2006;47:660-667.
10. Witzig TE, Fishkin P, Gordon LI, et al. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma. 2011;52:1188-1199.
11. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. 2003;30(1, suppl 2):3-8.
12. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium- 90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
13. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1989;7:1027-1038.
14. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:90-95.
15. Winter JN, Inwards DJ, Spies S, et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:1653-1659.
16. Song H, Du Y, Sgouros G, Prideaux A, Frey E, Wahl RL. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. J Nucl Med. 2007;48:150-157.
17. Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000;27: 766-777.
18. Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(suppl 1): 99S-106S.
19. Hobbs RF, Wahl RL, Lodge MA, et al. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med. 2009;50:1844-1847.
20. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007;48:1767-1776.
21. Frey E, He B, Sgouros G, Flinn I, Wahl R. Estimation of post-therapy marrow dose rate in myeloablative Y-90 ibritumomab tiuxetan therapy [abstract]. J Nucl Med. 2006;47(suppl 1):156P.
22. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985;58:515-528.
23. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679-694.
24. Rizvi SN, Visser OJ, Vosjan MJ, et al. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging. 2012;39:512-520.
25. Sgouros G, Squeri S, Ballangrud AM, et al. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44:260-268.
26. Hobbs RF, Sgouros G. Calculation of the biological effective dose (BED) for piece-wise defined dose-rate fits. Med Phys. 2009;36:904-907.
27. O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med. 1999;40:1337-1341.
28. Aref A, Mohammad R, Yudelev M, et al. Radiobiological characterization of two human chemotherapy-resistant intermediate grade non-Hodgkin's lymphoma cell lines. Radiat Oncol Investig. 1999;7:158-162.
29. Van Dyk J, Mah K, Keane TJ. Radiation-induced lung damage: dose-timefractionation considerations. Radiother Oncol. 1989;14:55-69.
30. Cremonesi M, Ferrari M, Bartolomei M, et al. Radioembolisation with 90Ymicrospheres: dosimetric and radiobiological investigation for multi-cycle treatment. Eur J Nucl Med Mol Imaging. 2008;35:2088-2096.
31. Hobbs RF, Baechler S, Wahl RL, et al. Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. J Nucl Med. 2010;51:368-375.
32. He B, Wahl RL, Sgouros G, et al. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning-patient studies. Med Phys. 2009;36:1595-1601.
33. Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm. 2003;18:89-97.
34. Brenner DJ, Hall EJ. Conditions for the equivalence of continuous to pulsed low dose rate brachytherapy. Int J Radiat Oncol Biol Phys. 1991;20:181-190.
35. Krishnan S, Lin EH, Gunn GB, et al. Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. Am J Clin Oncol. 2006;29:562-567.